Nanotherapies: A potent treatment for neurodegenerative diseases

Abstract

It is generally reported that neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, pose severe threats to global public health. Traditional therapies for neurodegenerative diseases exhibit low drug delivery efficiency due to the restrictive nature of the blood-brain barrier. Fortunately, nanomedicines can effectively overcome blood-brain barrier through mechanisms such as intercellular penetration and receptor targeting, which have advantages such as controlled release, reduced toxicity, and enhanced efficacy. In this paper, we summarize the latest research progress based on the types of nanomaterials, administration approach, and implications, with the aim of providing insights for optimizing the research and development of nanomedicines for neurodegenerative diseases.

Keywords

Nanotherapy / Neurodegenerative diseases / Drug delivery / Targeted delivery

Funding

This work was supported by the Natural Science Foundation of Guangdong Province under Grant No. 2025A1515010639.

Conflict of interest

The authors declare they have no competing interests.

References

[1] Biswas A, Hivare P, Solanki R, Gupta S, Bhatia D. Applications of bionanomaterials in neurodegenerative diseases. Mater Adv. 2025; 6(12):3785-3804. doi: 10.1039/D4MA01215A

[2] Rafe MR. Drug delivery for neurodegenerative diseases is a problem, but lipid nanocarriers could provide the answer. Nanotheranostics. 2024; 8(1):90-99. doi: 10.7150/ntno.88849

[3] Jiang Q, Liu J, Huang S, et al. Antiageing strategy for neurodegenerative diseases: From mechanisms to clinical advances. Signal Transduct Target Ther. 2025; 10:76. doi: 10.1038/s41392-025-02145-7

[4] Luo Q, Yang J, Yang M, et al. Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system. Mater Today Bio. 2025; 31:101457. doi: 10.1016/j.mtbio.2025.101457

[5] Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: Current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022; 23(3):1851. doi: 10.3390/ijms23031851

[6] Cui W, Fu W, Zhang T, Zhou R, Zhang T, Lin Y.Application of nanomaterials in neurodegenerative diseases. In: Lin Y, Zhou R, editors. Advances in Nanomaterials-Based Cell Biology Research. Berlin: Springer; 2021. p. 87-110. doi: 10.1007/978-981-16-2666-1_3

[7] López-Espinosa J, Park P, Holcomb M, Godin B, Villapol S. Nanotechnology-driven therapies for neurodegenerative diseases: A comprehensive review. Ther Deliv. 2024; 15(12):997-1024. doi: 10.1080/20415990.2024.2401307

[8] Dong N, Ali-Khiavi P, Ghavamikia N, et al. Nanomedicine in the treatment of Alzheimer’s disease: Bypassing the blood-brain barrier with cutting-edge nanotechnology. Neurol Sci. 2025; 46(4):1489-1507. doi: 10.1007/s10072-024-07871-4

[9] Akhtar A, Andleeb A, Waris TS, et al. Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. J Control Release. 2021; 330:1152-1167. doi: 10.1016/j.jconrel.2020.11.021

[10] Saeedi M, Eslamifar M, Khezri K, Dizaj SM. Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharmacother. 2019; 111:666-675. doi: 10.1016/j.biopha.2018.12.133

[11] Puranik N, Yadav D, Song M. Advancements in the application of nanomedicine in Alzheimer’s disease: A therapeutic perspective. Int J Mol Sci. 2023; 24(18):14044. doi: 10.3390/ijms241814044

[12] Andrade S, Ramalho MJ, Loureiro JA, Pereira MC. Transferrin-functionalized liposomes loaded with vitamin VB12 for Alzheimer’s disease therapy. Int J Pharm. 2022; 626:122167. doi: 10.1016/j.ijpharm.2022.122167

[13] Rafieezadeh D, Sabeti G, Khalaji A, Mohammadi H. Advances in nanotechnology for targeted drug delivery in neurodegenerative diseases. Am J Neurodegener Dis. 2025; 14(2):51-57. doi: 10.62347/QHVI3317

[14] Witika BA, Poka MS, Demana PH, et al. Lipid-based nanocarriers for neurological disorders: A review of the state-of-the-art and therapeutic success to date. Pharmaceutics. 2022; 14(4):836. doi: 10.3390/pharmaceutics14040836

[15] Hansen AMB, Poulsen R, Von Gersdorff Jørgensen L, Hansen M. Polyquaternium polymers cause inflammatory response and alterations of the lipidome in Danio rerio larvae. J Hazard Mater Lett. 2024; 5:100095. doi: 10.1016/j.hazl.2023.100095

[16] Lou J, Duan H, Qin Q, et al. Advances in oral drug delivery systems: Challenges and opportunities. Pharmaceutics. 2023; 15(2):484. doi: 10.3390/pharmaceutics15020484

[17] Zou Y, Zhang J, Chen L, Xu Q, Yao S, Chen H. Targeting neuroinflammation in central nervous system diseases by oral delivery of lipid nanoparticles. Pharmaceutics. 2025; 17(3):388. doi: 10.3390/pharmaceutics17030388

[18] Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019; 23:20. doi: 10.1186/s40824-019-0166-x

[19] Duan L, Li X, Ji R, et al. Nanoparticle-based drug delivery systems: An inspiring therapeutic strategy for neurodegenerative diseases. Polymers (Basel). 2023; 15(9):2196. doi: 10.3390/polym15092196

[20] Wu X, Zang R, Qiu Y, et al. Intranasal drug delivery technology in the treatment of central nervous system diseases: Challenges, advances, and future research directions. Pharmaceutics. 2025; 17(6):775. doi: 10.3390/pharmaceutics17060775

[21] Passeri E, Elkhoury K, Morsink M, et al. Alzheimer’s disease: Treatment strategies and their limitations. Int J Mol Sci. 2022; 23(22):13954. doi: 10.3390/ijms232213954

[22] Georgeous J, AlSawaftah N, Abuwatfa WH, Husseini GA. Review of gold nanoparticles: Synthesis, properties, shapes, cellular uptake, targeting, release mechanisms and applications in drug delivery and therapy. Pharmaceutics. 2024; 16(10):1332. doi: 10.3390/pharmaceutics16101332

[23] Guo X, Lie Q, Liu Y, et al. Multifunctional selenium quantum dots for the treatment of Alzheimer’s disease by reducing Aβ-neurotoxicity and oxidative stress and alleviate neuroinflammation. ACS Appl Mater Interfaces. 2021; 13(26):30261-30273. doi: 10.1021/acsami.1c00690

[24] Yang M, Jin L, Wu Z, et al. PLGA-PEG nanoparticles facilitate in vivo anti-Alzheimer’s effects of fucoxanthin, a marine carotenoid derived from edible brown algae. J Agric Food Chem. 2021; 69(34):9764-9777. doi: 10.1021/acs.jafc.1c00569

[25] Zhang X, Hu H, Li Q, et al. Cascade-targeting multifunctional nanochaperone remodels brain microenvironment for synergistic therapy of Alzheimer’s disease. Nano Today. 2024; 55:102168. doi: 10.1016/j.nantod.2024.102168

[26] Emamzadeh FN, Surguchov A. Parkinson’s disease: Biomarkers, treatment, and risk factors. Front Neurosci. 2018; 12:612. doi: 10.3389/fnins.2018.00612

[27] Teixeira MI, Lopes CM, Gonçalves H, et al. Formulation, characterization, and cytotoxicity evaluation of lactoferrin functionalized lipid nanoparticles for riluzole delivery to the brain. Pharmaceutics. 2022; 14(1):185. doi: 10.3390/pharmaceutics14010185

[28] Shukla R, Srivastava V, Sethi A, Ruwali M. Nanomaterial-based drug delivery systems as tools for targeted therapy of neurodegenerative diseases. In: Yadav AK, Shukla R, Flora SJS, editors. Nanomedical Drug Delivery for Neurodegenerative Diseases. Ch. 15. United States: Academic Press; 2022. p. 243-259. doi: 10.1016/B978-0-323-85544-0.00003-4

[29] Zakharova L, Gaynanova G, Vasilieva E, et al. Recent nanoscale carriers for therapy of Alzheimer’s disease: Current strategies and perspectives. Curr Med Chem. 2023; 30(33):3743-3774. doi: 10.2174/0929867330666221115103513

[30] Vashist A, Manickam P, Raymond AD, et al. Recent advances in nanotherapeutics for neurological disorders. ACS Appl Bio Mater. 2023; 6(7):2614-2621. doi: 10.1021/acsabm.3c00254